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Abstract
Background/Aim. Acute non-A, non-B, non-C, non-D,
non-E hepatitis (non-A-E AH) is an acute disease of the
liver of unknown etiology for which one or more new, so
far undetected, hepatotropic viruses may be responsible.
The frequency of non-A-E AH ranges from 3.8% to 33.9%,
and therefore it has a significant place within current infec-
tology and hepatology. The aim of our study was to estab-
lish the frequency, clinical and biochemical characteristics,
natural course and outcome of non-A-E AH and compare
them with control groups affected by acute viral hepatitis A,
B and C. Methods. This descriptive-analytic prospective
study included 31 patients with non-A-E AH treated at the
Institute of Infectious and Tropical Diseases, Clinical Cen-
ter of Serbia, Belgrade, from 2003 to 2008. They were fol-
lowed up during the period not less than 6 months. The
controls involved randomly selected patients, treated at the
same time with a definite diagnosis of acute viral hepatitis
A, B and C. Statistical data analysis used Mann-Whitney U-
test, Student’s t-test and variance analysis. The value of
p <  0.05 was considered statistically significant. Results.
The frequency of non-A-E AH was 7.6%. Almost no dif-
ference was found between sexes (male/female ratio was
1 : 1.07); it was developed in all age groups, with the highest
incidence in the middle age (mean age was 38.32  ±  15.3
years). It appeared equally throughout the whole year. Out
of risk factors, inoculation risk was predominant (before all,
dental interventions), mostly involving urban population
living in comfortable conditions. The duration of incubation
varied much ranging from 20 to 180 days (median 60 days).
By clinical course, moderate and icteric forms were most
common, mostly corresponding to acute hepatitis A and C.
On the other hand, by duration of the disease (mean dura-
tion was 67.1 ± 27.1) and chronic transformation, non-A-E
AH resembled to acute hepatitis B. Progression to chronic-
ity was recorded in 9.68% of the patients. There was no
fulminant neither cholestatic form of the disease. Conclu-
sion. Based on the results obtained in this study, it is prob-
able that there are some so far undetected primary hepato-
tropic viruses in our environment.
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Apstrakt
Uvod/Cilj. Akutni hepatitis ni A, ni B, ni C, ni D, ni E
(AH ni A-E) predstavlja akutno zapaljensko oboljenje jetre
nepoznate etiologije za koje bi mogao biti odgovoran je-
dan ili više novih, do sada neotkrivenih, hepatotropnih vi-
rusa. Učestalost AH ni A-E kreće se od 3,8% do 33,9%, te,
stoga, predstavlja značajno mesto u današnjoj infektologiji
i hepatologiji. Cilj rada bio je da se utvrdi učestalost, klini-
čke i biohemijske karakteristike, prirodni tok i ishod AH ni
A-E i da se uporedi sa kontrolnim grupama obolelih od
akutnog virusnog hepatitisa A, B i C. Metode. Deskripti-
vnoanalitičkom studijom prospektivnog karaktera bio je
obuhvaćen 31 bolesnik sa AH ni A-E koji su lečeni od
2003. do 2008. godine. Praćeni su u vemenskom periodu
od najmanje šest meseci. Kontrolne grupe činili su boles-
nici izabrani metodom slučajnog izbora, lečeni u istom
vremenskom periodu sa postavljenom dijagnozom akut-
nog virusnog hepatitisa A, B i C. Za statističku obradu po-
dataka korišćeni su Mann–Whitney U-test, Studentov t-
test i analiza varijanse. Vrednost p < 0,05 smatrana je stati-
stički značajnom. Rezultati. Učestalost AH ni A-E izno-
sila je 7,6%. Gotovo da nije bilo razlike u zastupljenosti
ovog hepatitisa među polovima (odnos muško  :  žensko
bio je 1 : 1,07); javljao se u svim uzrastima, sa najvećom
učestalošću u srednjem životnom dobu (prosečna starost
bila je 38,32 ± 15,3 godine). Podjednako se javljao tokom
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tvo inokulacionih rizika (pre svega stomatoloških inter-
vencija), pri čemu je većinom obolevalo gradsko stanovni-
štvo koje živi u konfornim životnim uslovima. Dužina in-
kubacije bila je veoma varijabilna i kretala se od 20 do 180
dana (medijana 60 dana). Po kliničkom toku, najčešće bile
su blaže i ikterične forme bolesti koje najviše odgovaraju
akutnom hepatitisu A i C. S druge strane, po dužini traja-
nja bolesti (prosečno trajanje bolesti iznosilo je 67,1 ± 27,1
dan) i prelasku u hronicitet, AH ni A-E odgovarao je
akutnom hepatitisu B. Progresija u hronicitet zabeležena je
kod 9,68% obolelih. Nije bilo fulminantnog, ni holestaz-
nog oblika bolesti. Zaključak. Na osnovu rezultata dobi-
jenih u ovoj studiji, vrlo je verovatno postojanje još nekih,
do sada neotkrivenih, primarno hepatotropnih virusa u na-
šoj sredini.
Ključne reči:
hepatitis, virusni; epidemiologija; bolest, prenošenje;
bolest, progresija; faktori rizika; prognoza.
Introducton
Acute non-A, non-B, non-C, non-D, non-E (hereinaf-
ter non-A-E AH) hepatitis is an acute inflammatory disease
of the liver of unknown etiology with all clinical and bio-
chemical characteristics of acute viral hepatitis, possibly
caused by some new hepatotropic virus. As a term, non-A-
E AH was first mentioned in 1995, when it was noted that,
in spite of two newly discovered hepatotropic viruses,
hepatitis C (HCV) and hepatitis E (HEV), there was still a
significant number of patients affected by acute hepatitis of
unknown origin 
1. In addition, among patients with chronic
hepatitis and liver cirrhosis, there have been cases with un-
detectable etiological factor of disease 
2. For this reason,
attempts have been made in view of focusing on identifica-
tion of new etiological entities. In time, three new hepato-
tropic viruses were discovered: GB virus (GBV-C) – also
named hepatitis G virus (HGV) in 1995, Torque Teno Vi-
rus (TTV) in 1997 and SEN virus (SENV) in 2000 
3–5. So
far, data have indicated that none of these three newly de-
tected viruses had had an important role, although there
have been some indications that a small number of the af-
fected patients may had been associated with acute, anic-
teric hepatitis to a large extent.
Non-A-E AH is an exclusive diagnosis, that is, a diag-
nosis of exclusion. It involves an acute inflammatory liver
disease with unknown origin in spite of thorough examina-
tions. Differential diagnosis should rule out acute infection
primarily caused by hepatotropic viruses, namely de novo in-
fection HAV, HBC, HCV and HEV, autoimmune liver dis-
ease (autoimmune hepatitis, primary biliary cirrhosis), meta-
bolic liver diseases (Wilson’s disease, hemochromatosis, al-
pha-1-antitripsin deficit), as well as toxic liver impairment
(alcoholic drinks, drugs, different toxins). Practically, it is
necessary to exclude any known etiological factor inducing
the picture of the acute hepatitis, in order to make diagnosis
of non-A-E AH. There is still very few prospective studies
dealing with these problems, requiring lots of time and re-
sources, and such issue holds a significant place in present
infectology and hepatology.
The objective of our study was to establish epidemiol-
ogical and clinical-biochemical characteristics, duration,
natural course and outcome of non-A-E AH, and to compare
basic characteristics of these patients with the controls af-
fected by acute viral hepatitis A, B and C.
Methods
This descriptive–analytic prospective study included the
patients treated in the Institute of Infectious and Tropical
Diseases, Clinical Center of Serbia, Belgrade, in the period
from 2003 to 2008. The study involved a total of 408 patients
with acute hepatitis, out of whom 31 patients (7.6%) had
been diagnosed with non-A-E AH. Diagnosis of non-A-E
AH was based on no history of chronic liver disease, pres-
ence of typical symptoms and signs, alanin aminotransferase
level (ALT) at least 8 times higher than the upper limit (ie.
41 UI/L) as well as ruling out of known factors of hepato-
cellular impairment. Actually, these patients had negative
markers for viral hepatitis A, B, C, and E (serology included
patient’s serum tests by ELISA for the presence of IgM and
IgG antibodies against above mentioned hepatotropic vi-
ruses, followed by PRC technique which verified the absence
of HCV RNA and HBV DNA in patient’s blood). In addi-
tion, the infection by other potential hepatotropic viruses
(CMV, EBV, HSV) was ruled out. Hepatitis caused by spir-
its, medicaments and other potential hepatotoxins was ruled
out by obtaining a detailed medical history through inter-
viewing the patients, as well as clinical and biochemical
evaluation of patients. Autoimmune hepatitis was excluded
by the absence of autoantibodies against nuclear (ANA),
smooth muscle (ASMA) and microsomal (anti-LKM1) anti-
gens, while primary biliary cirrhosis was ruled out by veri-
fying the absence of the antimitochondrial autoantibodies
(AMA). Metabolic liver diseases were ruled out upon deter-
mination of serum ceruloplasmin and copper levels, then
24/hour urine copper level – Wilson’s disease, normal serum
iron level and a total iron-binding capacity (TIBC) – hemo-
chromatosis, as well as normal serum alpha-1-antitripsin
level - alpha-1-antitripsin deficit.
The study included epidemiological analysis and clini-
cal-biochemical monitoring of patients with non-A-E AH,
and comparison with the controls affected by acute viral
hepatitis A, B and C.
The group non-A-E AH consisted of 31 patients. Out of
this number, 24 patients (77.42%) were followed-up during
at least 6-month period for determination of possible chronic
development, while 7 cases were lost to follow-up after
completed hospital treatment or were followed less than 6-
month period.
The controls comprised of three groups of patients, also
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Belgrade within the same period of time, which were ran-
domly selected. The goup I consisted of 35 patients with
hepatitis A. The group II included patients with acute hepati-
tis B, and the group III involved 19 controls affected by
acute hepatitis C. Table 1 shows the basic characteristics of
the study patients. All the patients were exclusively treated
by symptomatic therapy, so it may be considered they had
natural and spontaneous course of the disease.
Clinical and epidemiological examinations assumed an
identification of the incubation period – time period from the
contact with an affected person or the existing inoculation
risk factors (intravenous or nasal drug abuse, medical and
dental interventions, risky sexual intercourse, tattoo and
piercing) – to the onset of the initial symptoms and/or signs
of the disease, then duration of the disease in days (from the
first symptoms and/or signs of the disease to restoration of
clinical-biochemical findings to normal), symptomatology
and clinical forms of the disease. The patients were followed
in time period not less than 6 months with a view to ascertain
probable chronic development of the condition. Biochemical
analyses included measurement of transaminases – aspartat
aminotransferase (AST) and ALT levels, serum bilirubin
level (total and direct), alkaline phosphatase, gamma-
glutamyl transferase and prothrombin time. The controls un-
derwent the same examinations.
Statistical data analysis used the Mann-Whitney U-test,
Student’s  t-test and variance analysis with post hoc LSD
(Least Significant Difference) test. The initial statistical sig-
nificance was set at p < 0.05. Data processing was done by
SPSS package for Windows version 11.0.
Results
During a 6-year period, a total of 408 patients with
acute hepatitis was examined and treated; the frequency of
non-A-E AH was 7.6% (31 patients). The remaining 377 pa-
tients (92.4%) had acute hepatitis of known etiology: 146
(35.7%) had hepatitis A, 150 (36.8%) had acute hepatitis B,
57 (14.0%) acute hepatitis C, while only 1 (0.25%) had
hepatitis E. Ten patients (2.5%) were diagnosed with toxic
hepatitis and 13 (3.2%) with autoimmune hepatitis.
In the non-A-E AH group, sex ratio was 1 : 1.07 in fa-
vor of females, and the patients were mostly middle-aged
people. Twenty-four patients (77.4%) lived in urban envi-
ronment, 3 (9.7%) in suburban and 4 (12.9%) in the country.
The majority of patients, 25 (81.4%) had comfortable living
conditions (meaning primarily the source of drinking water
and disposition of waste material). More than a half, ie. 17
cases (55.9%), had secondary school qualifications, 4
(14.8%) had elementary school education, 7 had col-
lege/university degree (22.2%) and 3 patients (11.1%) were
retired.
Empirically, the disease most frequently appeared in
winter – 14 patients (45.2%), in spring and autumn got ill 6
patients (19.4%), respectively and in summer 5 patients
(16.1%). In spite of that fact, there was no statistical signifi-
cance (p = 0.078), indicating that non-A-E AH occurred in
all seasons, that is, throughout the year.
Regarding risk factors and possible transmission
pathways, 15 patients (48.4%) had some of the risk fac-
tors of viral hepatitis of known etiology 6 months before
the onset of the first symptoms and signs of disease. Fig-
ure 1 illustrates the percentage incidence of risk factors.
The majority of patients, even 11 (35.5%), had some of
the inoculation risk factors, while only one (3.3%) used to
travel to the region characterized by endemic viral hepa-
titis with fecal-oral transmission. The remaining 16
(51.6%) did not mention in their medical history any of
possible risk factors.
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Fig. 1 –  Frequency of possible risk factors (%)  among
patients suffering from acute non A-E hepatitis
The incubation period for the subjects with known risk
factors was rather varying and ranged from 20 to 180 days,
with median of 60 days. Out of 31 patients, only 1 (3.2%)
had asymptomatic form, and his acute hepatitis was de-
tected accidentally by biochemical analyses. Other 30 cases
(96.8%) had a manifest form of the disease. Sudden onset
of the disease was reported in 29 patients (93.5%) and
gradual was manifested in only 1 case (3.2%). The mean
time from the onset of the initial symptoms and/or signs to
Table 1
Characteristics of the patients involved in the study
Acute viral
hepatitis (AVH) Total number
of patients
Male
n         %
Female
    n           %
Average age of the
patients (years)
(ґ ± SD)
Range of age
(years)
non-A-E AH 31 15        48.4 16       51.6 38.32 ± 15.30 17–76
AVH A 35 20        57.1 15       42.9 30.03 ± 10.68 10–51
AVH B 31 15        48.4 16       51.6 36.42 ± 14.55 17–73
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hospitalization was 13.5  ±  10.6 days (median 10 days),
varying from 5-45 days. Icterus was present in 24 patients
(77.1%), and others were anicteric. An average duration of
the icteric phase (in those having the icterus) was
20.3 ± 15.7 (median 14.5 days), and ranged form 6 to 64
days. Among other symptoms and signs, fatigue and mal-
aise as well as nausea and feel sickened were the most fre-
quent, while other symptoms and signs pathognomonic for
acute hepatitis were slightly less frequent. Synovitis and
rash as immunologically-mediated manifestations of acute
hepatitis B were present in 6 (19.4%) and 5 (16.1%) pa-
tients, respectively (Table 2).
Table 2
Symptoms and signs of acute non-A-E hepatitis
Symptoms and signs Patients
n         %
Fatigue and malaise 21      67.8
Nausea and queasiness 21      67.8
Vomiting 16      51.6
Abdominal pain 12       38.7
Anorexia 12       38.7
High fever 10       32.3
Arthralgias 6       19.4
Rash 5       16.1
Diarrhoea 5       16.1
There were no cholestatic or fulminant forms of dis-
eases in our study.
Out of 24 patients followed-up for sufficient period of
time, 21 (87.5%) had self-limited disease which resulted in
complete recovery. Chronic hepatitis was developed in
three patients (12.5%), what was histopathologically veri-
fied by liver bioptic specimen analysis. Mean duration of
the disease in cured cases was 67.1 ± 27.1 days, ranging
from 29 to 129 days.
Comparison of the non-A-E AH group to the group
with acute viral hepatitis of known etiology showed that dis-
tribution by sex was similar in the controls, except for the
group of acute hepatitis C. Regarding the latter group, a sig-
nificant difference was found (p < 0.05), meaning that males
were more frequently affected by the disease.
In relation to age, the majority of cases with non-A-E
AH belonged to the middle age group, as well as to the group
of acute hepatitis B. On the other hand, acute hepatitis A and
C were more frequently reported in younger age and it was
statistically significant (p < 0.05) (Table 3).
Comparison of biochemical characteristics of the non-
A-E AH group and the controls revealed that the patients
with acute viral hepatitis B had more manifested icterus
(higher bilirubin values) and more impaired hepatic synthesis
function. The groups with acute hepatitis A and B presented
higher degree of hepatocellular necrosis, manifested by
higher serum transaminase levels. According to other bio-
chemical parameters, the non-A-E AH group did not signifi-
cantly differ from the controls (Table 4).
The mean duration of disease, from the onset of the first
symptoms and signs to the normalization of clinical-
biochemical findings was significantly longer in the non-A-E
AH group in relation to the controls with acute viral hepatitis
A and C. Statistically, the duration of the disease was similar
between the non-A-E AH and the acute hepatitis B group
(Table 5).
Table 3
Age of the patients in the group with acute non-A-E hepatitis
and the control groups
 Acute viral
hepatitis (AVH)
Patients' age (years)
ґ ± SD
p 
Non-A-E AH 38.3 ± 15.3 –
AVH A 30.0 ± 10.7   0.009
AVH B 36.4 ± 14.5 0.554
AVH C 26.5 ± 5.7  0.002
Table 4
Biochemical characteristics of patients with non-A-E AH and AVH A, B and C
Biochemical
parameters
Non-A-E AH
ґ ± SD
AVH A
ґ ± SD
AVH B
ґ ± SD
AVH C
ґ ± SD
AST (U/L) 740.9 ± 477.8 1146.4 ± 848.4* 1006.1 ± 570.1* 728.9 ± 352.2
ALT (U/L) 1348.3 ± 919.3 2273.9 ± 1143.5 1855.1 ± 1054.9 1521.1 ± 864.1
γ–GT (U/L) 212.9 ± 249.7 324.6 ± 291.3 225.1 ± 223.9 162 ± 101.1
AP           (U/L) 245.3 ± 292.5 247.9 ± 98.9 240.6 ± 147.6 172 ± 55.5
Total  serum bili-
rubin (μmol/L) 117.9 ± 123.5 121.6 ± 52.2 231.8 ± 120.4 130.9 ± 126.8
Direct serum bili-
rubin (μmol/L) 73.9 ± 93.5 79.9 ± 39.8* 153.6 ± 83.1* 71.4 ± 73.0
PT (%) 73.4 ± 16.4 70.9 ± 15.9 60.7 ± 15.4* 75.2 ± 15
*p < 0,05; AVH – acute viral hepatitis; AST – aspartate aminotransferase; ALT – 
 alanine aminotransferase;
γ–GT  – gamma glutamyltransferase;  AP – alkaline phosphatase; PT – 
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Table 5
Averge duration of the acute viral hepatitis
Acute viral hepatitis
(AVH)
Disease  duration (days)
   ґ ± SD
p
Non-A-E AH 67.1 ± 27.1 –
AVH A 52.8 ± 9.0 0.003
AVH B 64.5 ± 16.4 0.10
AVH C 56.3 ± 19.0 0.000
Discussion
The incidence of non-A-E AH in the patients involved
in our study accounted for 7.6%. The incidence in studies of
other medical centers worldwide ranged from 3.8% in re-
cently completed study in Greece to even 33.9%, as reported
in the study from Italy 
6, 7.
In different studies, age of non-A-E AH patients var-
ied to a large extent ranging from 8 up to 83 years 
8, 9, while
in our study most commonly diseased patients were
younger people, ie. the oldest was 51. Similarly, sex ratio
was rather disproportional, ranging from 3.8 : 1 in favor of
males to 2 : 1 in favor of females 
10, 11. In our study, this ra-
tio was pretty even. These data indicate that there is no
specific predomination in contracting this disease either by
sex or age.
Clinically, non-A-E AH severity varies between stud-
ies. However, we have to emphasize that different research-
ers use different criteria in defining this condition. The most
frequent indicators have been prothrombin time, serum al-
bumin value, bilirubinemia level, the presence of encepha-
lopathy, duration of disease, or any of their specific combi-
nation. Generally, the reference data suggest that non-A-E
AH is by severity similar to acute hepatitis C and moderate
clinical forms are more common 
9–11. In our study, non-A-E
AH was similar by severity both to acute hepatitis C and A,
while on the other hand, the patients with acute hepatitis B
mostly had more severe clinical image (given the higher de-
gree of hepatocellular necrosis, more manifested icterus and
prolonged prothrombin time). Nevertheless, in relation to the
duration of the disease and hospitalization, non-A-E AH cor-
responded to acute hepatitis B, while in acute hepatitis A and
C, the disease duration was significantly shorter. No patient
of our study with non-A-E AH developed fulminant or cho-
lestatic form of disease. Contrary to these findings, in the
majority of medical centers worldwide, the fulminant hepati-
tis has occurred in a certain percentage, accounting mostly
for 5% 
6, 10, 12. Non-A-E AH is usually self-limited disease
and most commonly results in a complete recovery. In spite
of that fact, chronic transformation has been recorded in
varying percentage, from 6.5% 
10 to 27.3% 
6, depending on
the type of research. In our patients, chronic transformation
was recorded in 12.5% that was close to the known fact of
chronic transformation from acute hepatitis B and signifi-
cantly lesser from acute hepatitis C 
13, 14.
Regarding risk factors and possible transmission path-
ways, the majority of current studies either have not detected
possible transmission pathways of non-A-E AH causes or
they have been recorded in a very small percentage. Thus,
Chu, et all. 
10 reported the information on travelling to en-
demic region of hepatitis with fecal-oral transmission ac-
counting for only 1.4% of the time, without any fact on par-
enteral risk, while Rochling et al. 
15 detected a parenteral risk
factor in 6% of the patients, in association with recent blood
transfusions. Some other researchers, such as Tassopoulos et
al. 
6, Paraná et al. 
12 and He et al. 
16 failed to identify any of
viral hepatitis transmission pathways of known origin. It
would be one of the major reasons for not having found any
relevant data on the duration of incubation so far. In distinc-
tion from these results, we recorded possible transmission
pathway of non-A-E AH in as high as 48.4% of patients.
They all were exposed to some of the parenteral risk factors,
and almost a half of them had recently undergone a type of
dental intervention. The risk of fecal-oral infection was re-
corded in considerably lower percentage. Considering the
significant number of cases with some of the risk factors of
the infection, the incubation period was determined in our
study and it lasted for 60 days (value of median). In compari-
son with incubation in the controls, it was established to be
similar to that in acute hepatitis B and C groups, and longer
in hepatitis A group.
One of the possible causative agents of non-A-E AH
may be HBV in the form of occult HBV infection, ie. per-
sistent HBV infection in the absence of the serologic mark-
ers. This kind of paradox may be accounted for mutations in
HBV genome leading to HBV modifications, which cannot
be detected by standard serologic analyses. Nevertheless,
HBV genome may be, in these cases, identified by more sen-
sitive PCR methods such as fluorescence quantitative PCR
(FQ-PCR) and nested PCR (nPCR). Therefore, having re-
searched possible non-A-E AH causes, He et al. 
16 found that
it was actually acute viral hepatis B responsible in 41.4% of
patients.
The cause may also be an occult HCV infection. Spe-
cifically, in the period prior to seroconversion, which may
even be absent 
17, HCV RNA level is very varying and there
is a possibility that it can not be detected by standard diag-
nostic procedures. These patients, initially diagnosed with
non-A-E AH, virtually have an acute HCV infection, which
may be established only when stable relation between virus
and host is constituted 
18.
As far as the newly detected hepatotropic viruses are
concerned, HGV/GBV-C, TTV and SENV, their role in de-
velopment of liver impairment has not been clarified yet.
But, HGV/GBV-C is mainly seen in younger people and
usually has the form of mild, subclinical or anicteric form of
the disease 
19. Fulminant forms are very rare. Principal path-
way of transmission is via blood transfusion, but it usually
does not cause hepatitis 
20. This is supported by the results of
the research in the USA showing that even 18%-20% of all
blood units prepared for transfusion contain HGV/GBV-C 
21.
The virus is ubiquitous and its incidence in non-A-E AH pa-
tients ranges from 3% according to research in Italy 
8 and
16% as reported by Brazilian studies 
12. In 2000, Delić et
al. 
22 also established the presence of HGV/GBV-C in Serbia,
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A novel DNA virus TTV, which is currently classified
in the family Circoviridae and genus Anellovirus, was ini-
tially detected in patients from Japan who had the acute
posttransfusion hepatitis of unknown etiology 
23. Since its
discovery in 1997, TTV was associated with different dis-
eases including acute and chronic liver disease, kidney and
pulmonary diseases, hematological conditions, various tu-
mors, but until these days its actual role as etiological fac-
tor has not been elucidated. It is primarily transmitted par-
enterally, but it has been also detected in feces, thus, fecal-
oral transmission cannot be ruled out 
24. It can be identified
in patients with non-A-E AH in high percent, from 21.4%
up to even 52.6% 
6 of cases, but whether it is the true
causative agent of acute hepatitis remains unclear. Explic-
itly, in all studies dealing with this issue, there has been
almost no difference between these patients and those
without TTV infection, or no relation of viremia and hepa-
tocellular damage extent 
25, 26. Moreover, TTV may be
identified in a high percentage in healthy blood donors
worldwide, so a study from Brazil revealed it in even 62%
of such cases 
27.
Similar situation to TTV is with lately detected hepato-
tropic virus SENV. It is very variable virus, similar to TTV,
and it is assumed they both originated from the common
progenitor. So far, eight SENV genotypes have been identi-
fied, from which important genotypes for human infectology
and hepatology are genotypes D and H. Its role in the devel-
opment of chronic liver diseases has not been clearly defined
while its participation in acute posttransfusion hepatitis is
more expectable 
28. In patients with serum non-A-E AH,
SENV was detected by the PCR technique in high percent-
age – from 27% as reported by study from Slovakia 
29 to
53.3% in China 
30. However, since these patients do not dif-
fer considerably from others affected by non-A-E AH with-
out SENV, as well as that SENV may be detected among
healthy blood donors in over 20% of the time 
31, its true role
is still vague.
Among other non-A-E AH causes, one cannot exclude
the possibility of toxic liver damage by other substances
which are not primarily identified as hepatotoxic. For exam-
ple, these will include any parts of different plants which
may be used as preparations in herbal medicine 
32.
Conclusion
There is a highly certified assumption that some other,
so far undetected, primary hepatotropic viruses may cause
both acute and chronic liver conditions. Such conclusion is
corroborated by our study results as well as by findings of
studies conducted worldwide. Accordingly, the future re-
search should be focused on their detection and defining
their role and significance.    
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